MXLIPO
MCID: MYX005
MIFTS: 64

Myxoid Liposarcoma (MXLIPO)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Myxoid Liposarcoma

MalaCards integrated aliases for Myxoid Liposarcoma:

Name: Myxoid Liposarcoma 57 12 75 53 74 37 29 13 15 17
Myxoid/round Cell Liposarcoma 12 53 59 72
Liposarcoma, Myxoid 44 40 72
Liposarcoma 59 72
Mrcls 53 59
Liposarcoma Myxoid 55
Myxoliposarcoma 53
Mxlipo 74

Characteristics:

Orphanet epidemiological data:

59
liposarcoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;
myxoid/round cell liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

HPO:

32
myxoid liposarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:5363
OMIM 57 613488
KEGG 37 H00049
MeSH 44 D018208
SNOMED-CT 68 27849002
MESH via Orphanet 45 D008080 D018208
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 73 C0023827 C0206634
MedGen 42 C0206634
UMLS 72 C0023827 C0206634 C0545074

Summaries for Myxoid Liposarcoma

NIH Rare Diseases : 53 Myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body's fat tissue. Other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. Round cell and myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (MRCLS). In adults, liposarcomas are the most common type of soft tissue sarcoma. The cause of liposarcomas is not well-established but trauma has been implicated in some cases. Myxoid liposarcomas generally arise in the lower extremities. Symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. Many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures. When possible, surgical removal is the preferred treatment. In some cases, additional therapy may be indicated. The prognosis is generally favorable for those with a low grade myxoid liposarcoma with a small percentage of round cells. A significant round cell component is associated with a poorer prognosis. Although these tumors rarely spread, they can recur if not completely removed.

MalaCards based summary : Myxoid Liposarcoma, also known as myxoid/round cell liposarcoma, is related to spindle cell liposarcoma and sclerosing liposarcoma. An important gene associated with Myxoid Liposarcoma is MXLPO (Myxoid Liposarcoma), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Cyclophosphamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and breast, and related phenotypes are subcutaneous nodule and abdominal pain

Disease Ontology : 12 A liposarcoma that is characterized by the presence of a hypocellular spindle cell proliferation set in a myxoid background and has material basis in chromosomal translocations.

OMIM : 57 Myxoid liposarcoma is a soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion (review by Dei Tos, 2000). (613488)

KEGG : 37
Liposarcoma(LS) represents the most common soft-tissue sarcoma of adults and occurs most often in the thigh and retroperitoneum. LSs are subclassified into well-differentiated, myxoid, round cell, and pleomorphic types. The myxoid type, the most common subtype, accounts for approximately 40% to 54% of all liposarcomas. The karyotypic hallmark of myxoid LS is the t(12;16)(q13;p11), present cytogenetically in >90% of the cases. The translocation leads to the fusion of the DDIT3(CHOP) and FUS(TLS) genes at 12q13 and 16p11, respectively, and the generation of a FUS-DDIT3 hybrid protein. In 4 cases of myxoid LS, a variant chromosomal translocation has been described, t(12;22), in which DDIT3 fuses instead with EWSR1(EWS), a gene highly related to TLS.

UniProtKB/Swiss-Prot : 74 Myxoid liposarcoma: A soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion.

Wikipedia : 75 A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance... more...

Related Diseases for Myxoid Liposarcoma

Diseases related to Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 489)
# Related Disease Score Top Affiliating Genes
1 spindle cell liposarcoma 34.2 MDM2 DDIT3 CDK4
2 sclerosing liposarcoma 34.2 TP53 MDM2 FUS
3 cellular myxoid liposarcoma 33.6 MDM2 HCCS FUS EWSR1 CDK4
4 pleomorphic lipoma 31.9 MDM2 HMGA2
5 soft tissue sarcoma 31.8 TP53 MDM2 EWSR1
6 well-differentiated liposarcoma 31.4 MDM2 HMGA2 CDK4
7 lipomatosis, multiple 31.4 MDM2 HMGA2 FUS CDK4
8 lipoblastoma 31.3 MDM2 CDK4
9 spindle cell lipoma 31.3 MDM2 CDK4
10 myxofibrosarcoma 31.3 MDM2 FUS
11 mesenchymoma 31.1 MDM2 HMGA2
12 infiltrating lipoma 31.0 MDM2 HMGA2 CDK4
13 pleomorphic adenoma 31.0 TP53 MDM2 HMGA2
14 leiomyosarcoma 30.9 TP53 MDM2 CDK4
15 mixed liposarcoma 30.9 MDM2 FUS DDIT3 CDK4
16 inflammatory mfh 30.8 MDM2 CDK4
17 sarcoma, synovial 30.8 MDM2 IGF1R HMGA2
18 inflammatory myofibroblastic tumor 30.7 TP53 MDM2 CDK4
19 malignant peripheral nerve sheath tumor 30.7 TP53 MDM2 CDK4
20 chondrosarcoma, extraskeletal myxoid 30.7 FUS EWSR1 DDIT3
21 embryonal sarcoma 30.6 TP53 MDM2 CDK4
22 extraosseous chondrosarcoma 30.6 FUS EWSR1
23 fibrous histiocytoma 30.5 FUS EWSR1 ATF1
24 chondroid lipoma 30.5 MDM2 FUS DDIT3 CDK4
25 dedifferentiated liposarcoma 30.5 TP53 MDM2 IGF1R HMGA2 CDK4
26 liposarcoma 30.4 TSN TP53 MDM2 LRP1 HMGA2 FUS
27 malignant mesenchymoma 30.3 TP53 MDM2 EWSR1 CDK4
28 rhabdomyosarcoma 30.1 TP53 MDM2 IGF1R EWSR1 CDK4
29 sarcomatosis 30.0 HMGA2 EWSR1 ATF1
30 clear cell sarcoma 30.0 FUS EWSR1 ATF1
31 histiocytoma 29.9 TP53 MDM2 FUS EWSR1 ATF1
32 glioblastoma multiforme 29.8 TP53 MDM2 IGF1R CDK4
33 connective tissue cancer 29.6 TP53 MDM2 FUS EWSR1 CDK4
34 glioblastoma 29.0 TP53 MIR486-1 MDM2 IGF1R CDK4
35 sarcoma 28.5 TP53 MDM2 FUS EWSR1 ERG DDIT3
36 ewing sarcoma 28.2 TP53 MDM2 IGF1R FUS EWSR1 ERG
37 myxoid liposarcoma of the ovary 12.8
38 kidney liposarcoma 12.5
39 larynx liposarcoma 12.5
40 inflammatory liposarcoma 12.3
41 cutaneous liposarcoma 12.3
42 pediatric liposarcoma 12.3
43 vulvar liposarcoma 12.3
44 adult liposarcoma 12.3
45 intracranial liposarcoma 12.3
46 fibroblastic liposarcoma 12.1
47 zika virus infection 10.6 TP53 MDM2
48 kidney fibrosarcoma 10.6 HMGA2 EWSR1
49 juxtacortical chondroma 10.6 HMGA2 FUS EWSR1
50 pleomorphic adenoma carcinoma 10.6 TP53 HMGA2

Graphical network of the top 20 diseases related to Myxoid Liposarcoma:



Diseases related to Myxoid Liposarcoma

Symptoms & Phenotypes for Myxoid Liposarcoma

Human phenotypes related to Myxoid Liposarcoma:

59 32 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 subcutaneous nodule 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001482
2 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002027
3 gastrointestinal dysmotility 59 32 occasional (7.5%) Occasional (29-5%) HP:0002579
4 nausea and vomiting 59 Occasional (29-5%)
5 fatigue 59 Occasional (29-5%)
6 weight loss 59 Occasional (29-5%)
7 paresthesia 59 Occasional (29-5%)
8 abnormality of the kidney 59 Occasional (29-5%)
9 sarcoma 59 Very frequent (99-80%)
10 varicose veins 59 Occasional (29-5%)
11 myxoid liposarcoma 32 HP:0012268

Clinical features from OMIM:

613488

MGI Mouse Phenotypes related to Myxoid Liposarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 CDK4 CEBPB DDIT3 ERG HCCS IGF1R
2 homeostasis/metabolism MP:0005376 10.1 CDK4 CEBPB DDIT3 ERG HCCS IGF1R
3 hematopoietic system MP:0005397 10.07 CDK4 CEBPB DDIT3 ERG IGF1R LRP1
4 endocrine/exocrine gland MP:0005379 10.06 CDK4 CEBPB DDIT3 ERG IGF1R MDM2
5 immune system MP:0005387 9.96 CDK4 CEBPB DDIT3 ERG IGF1R LRP1
6 adipose tissue MP:0005375 9.93 CEBPB DDIT3 IGF1R LRP1 TP53 TSN
7 liver/biliary system MP:0005370 9.7 CDK4 CEBPB DDIT3 IGF1R LRP1 MDM2
8 muscle MP:0005369 9.5 CDK4 CEBPB HCCS IGF1R LRP1 MDM2
9 neoplasm MP:0002006 9.17 CDK4 CEBPB DDIT3 ERG IGF1R MDM2

Drugs & Therapeutics for Myxoid Liposarcoma

Drugs for Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
2
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
5
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Epirubicin Approved Phase 3 56420-45-2 41867
10
Etoposide Approved Phase 3 33419-42-0 36462
11
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13 Olaratumab Approved, Investigational Phase 3 1024603-93-7
14
Ifosfamide Approved Phase 3 3778-73-2 3690
15
Histamine Approved, Investigational Phase 3 51-45-6 774
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17 Immunosuppressive Agents Phase 3
18 Antirheumatic Agents Phase 3
19 Pharmaceutical Solutions Phase 3
20 Nucleic Acid Synthesis Inhibitors Phase 3
21 Antineoplastic Agents, Phytogenic Phase 3
22 Tubulin Modulators Phase 3
23 Etoposide phosphate Phase 3
24 Antimitotic Agents Phase 3
25 Anti-Bacterial Agents Phase 3
26 Antibiotics, Antitubercular Phase 3
27
Liposomal doxorubicin Phase 3 31703
28 Topoisomerase Inhibitors Phase 3
29
Isophosphamide mustard Phase 3 0
30 Gastrointestinal Agents Phase 3
31 Neurotransmitter Agents Phase 3
32 Anti-Allergic Agents Phase 3
33 Serotonin Antagonists Phase 3
34 Histamine H1 Antagonists Phase 3
35 Histamine Antagonists Phase 3
36 Dermatologic Agents Phase 3
37 Serotonin Agents Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Antipruritics Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
42
Mecasermin Approved, Investigational Phase 2 68562-41-4
43
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
46
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
49
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
4 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
5 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
6 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
7 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
8 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
11 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
12 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
13 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
14 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
15 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
17 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
18 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
19 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
20 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
21 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
22 A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation Unknown status NCT00633165 Phase 2 Brostallicin
23 Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Unknown status NCT02275286 Phase 1, Phase 2 Trabectedin
24 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
25 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
26 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
27 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
28 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
29 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
30 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Completed NCT02609984 Phase 2
31 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Completed NCT00642941 Phase 2 RG1507
32 SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES Completed NCT02066675 Phase 2 Trabectedin
33 A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
34 Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma Completed NCT00003058 Phase 2 troglitazone
35 Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
36 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
37 A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
38 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
39 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
40 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
41 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
42 Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
43 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
44 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
45 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
46 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
47 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
48 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
49 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
50 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate

Search NIH Clinical Center for Myxoid Liposarcoma

Cochrane evidence based reviews: liposarcoma, myxoid

Genetic Tests for Myxoid Liposarcoma

Genetic tests related to Myxoid Liposarcoma:

# Genetic test Affiliating Genes
1 Myxoid Liposarcoma 29

Anatomical Context for Myxoid Liposarcoma

MalaCards organs/tissues related to Myxoid Liposarcoma:

41
Bone, T Cells, Breast, Adipocyte, Testes, Liver, Kidney

Publications for Myxoid Liposarcoma

Articles related to Myxoid Liposarcoma:

(show top 50) (show all 888)
# Title Authors PMID Year
1
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. 9 38 8
7503811 1993
2
Genomic PCR detects tumor cells in peripheral blood from patients with myxoid liposarcoma. 38 8
8913727 1996
3
Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3. 38 8
8453640 1993
4
A case of myxoid liposarcoma with translocation t(12;16) as the only abnormality. 38 8
3395985 1988
5
A complex translocation involving chromosomes 12 and 16 in a metastatic myxoid liposarcoma. 38 8
3395986 1988
6
Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter. 38 8
2823744 1987
7
The human int-1 gene is located at chromosome region 12q12-12q13 and is not rearranged in myxoid liposarcoma with t(12;16) (q13;p11). 38 8
3329717 1987
8
Clonal chromosome abnormalities in two liposarcomas. 38 8
3607734 1987
9
Lipomas have characteristic structural chromosomal rearrangements of 12q13-q14. 38 8
3473046 1987
10
Translocation t(12;16) in a case of myxoid liposarcoma. 38 8
3470133 1987
11
Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). 8
1283316 1992
12
Localization of the chromosomal breakpoints of the t(12;16) in liposarcoma to subbands 12q13.3 and 16p11.2. 8
2372777 1990
13
The INT1 oncogene is not rearranged or amplified in lipomas with structural chromosomal abnormalities of 12q13-15. 8
2790742 1989
14
Different karyotypic features characterize different clinico-pathologic subgroups of benign lipogenic tumors. 8
3192332 1988
15
Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. 8
3402992 1988
16
Reciprocal translocation t(3;12)(q27;q13) in lipoma. 8
3779626 1986
17
Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. 8
3779625 1986
18
Recurrent chromosome translocations in liposarcoma. 8
3955533 1986
19
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. 9 38
19190116 2009
20
Translocations and amplifications of chromosome 12 in liposarcoma demonstrated by the LSI CHOP breakapart rearrangement probe. 9 38
18517278 2008
21
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. 9 38
18214854 2008
22
The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. 9 38
18162764 2008
23
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. 9 38
16849546 2006
24
Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. 9 38
12915480 2003
25
RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. 9 38
12168660 2002
26
Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. 9 38
11063792 2000
27
CHOP/GADD153 and methionyl-tRNA synthetase (MetRS) genes overlap in a conserved region that controls mRNA stability. 9 38
10448063 1999
28
[Genetic studies of differential fatty tissue tumor diagnosis]. 9 38
9244875 1997
29
Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. 9 38
9071998 1997
30
Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins. 9 38
8954779 1996
31
Fusion of the EWS and CHOP genes in myxoid liposarcoma. 9 38
8637704 1996
32
Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). 9 38
7566973 1995
33
The emerging molecular genetics of sarcoma translocations. 9 38
7493135 1995
34
The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas. 9 38
7828148 1994
35
A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. 9 38
7958914 1994
36
An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. 9 38
8187069 1994
37
No rearrangements of the CHOP gene in malignant fibrous histiocytoma. 9 38
8143276 1994
38
CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. 9 38
8125258 1994
39
The 12q13-q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma of tendons and aponeuroses are different from that in myxoid liposarcoma. 9 38
7687873 1993
40
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. 9 38
8510758 1993
41
Sonographic Appearances of Liposarcoma: Correlations with Pathologic Subtypes. 38
31202456 2019
42
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. 38
31296491 2019
43
Case reports of diagnostic error: liposarcoma mistaken for hematoma in an obese female with concurrent ipsilateral thrombosis on rivaroxaban. 38
30511930 2019
44
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. 38
31409911 2019
45
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. 38
31171504 2019
46
The FUS-DDIT3 Interactome in Myxoid Liposarcoma. 38
31220736 2019
47
Head and neck pleomorphic myxoid liposarcoma in a child with Li-Fraumeni syndrome. 38
31129458 2019
48
Lipomatous Tumors in Pediatric Patients: A Retrospective Analysis of 50 cases. 38
31282548 2019
49
Myxoma versus myxoid liposarcoma involving the kidneys. 38
31384201 2019
50
Malignant intestinal obstruction during twin pregnancy: surgical resection of a myxoid liposarcoma without induction of labour. 38
31289166 2019

Variations for Myxoid Liposarcoma

Cosmic variations for Myxoid Liposarcoma:

9 (show top 50) (show all 217)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6978413 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 16
2 COSM3054546 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 16
3 COSM6987297 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.223G>A p.E75K 11:32434919-32434919 16
4 COSM6986268 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 16
5 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 16
6 COSM10648 TP53 soft tissue,fat,liposarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 16
7 COSM10672 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 16
8 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 17:7675208-7675208 16
9 COSM10656 TP53 soft tissue,fat,liposarcoma,pleomorphic c.742C>T p.R248W 17:7674221-7674221 16
10 COSM45794 TP53 soft tissue,fat,liposarcoma,pleomorphic c.421T>G p.C141G 17:7675191-7675191 16
11 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 16
12 COSM43632 TP53 soft tissue,fat,liposarcoma,pleomorphic c.493C>T p.Q165* 17:7675119-7675119 16
13 COSM10731 TP53 soft tissue,fat,liposarcoma,pleomorphic c.707A>G p.Y236C 17:7674256-7674256 16
14 COSM6848516 TET2 soft tissue,fat,liposarcoma,myxoid-round cell c.3809C>T p.T1270I 4:105259624-105259624 16
15 COSM6921522 SDHA soft tissue,fat,liposarcoma,myxoid-round cell c.664T>G p.L222V 5:228227-228227 16
16 COSM1437480 RICTOR soft tissue,fat,liposarcoma,pleomorphic c.3404C>T p.T1135M 5:38950444-38950444 16
17 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 13:48456207-48456207 16
18 COSM6966300 RB1 soft tissue,fat,liposarcoma,pleomorphic c.2632G>A p.D878N 13:48476812-48476812 16
19 COSM6906362 RAF1 soft tissue,fat,liposarcoma,pleomorphic c.1141G>A p.D381N 3:12591760-12591760 16
20 COSM5106 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.335T>C p.L112P 10:87933094-87933094 16
21 COSM5135 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.106G>A p.G36R 10:87894051-87894051 16
22 COSM5039 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.518G>A p.R173H 10:87952143-87952143 16
23 COSM1167954 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.485A>T p.D162V 10:87933244-87933244 16
24 COSM3416650 POLE soft tissue,fat,liposarcoma,myxoid-round cell c.2275C>T p.R759C 12:132667547-132667547 16
25 COSM6987724 PLK2 soft tissue,fat,liposarcoma,myxoid-round cell c.1337G>C p.R446P 5:58456073-58456073 16
26 COSM775 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3140A>G p.H1047R 3:179234297-179234297 16
27 COSM760 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1624G>A p.E542K 3:179218294-179218294 16
28 COSM754 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1035T>A p.N345K 3:179203765-179203765 16
29 COSM12597 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3145G>C p.G1049R 3:179234302-179234302 16
30 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 3:179218303-179218303 16
31 COSM6903888 NOTCH2 soft tissue,fat,liposarcoma,myxoid-round cell c.5857C>T p.R1953C 1:119918478-119918478 16
32 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 17:31201079-31201079 16
33 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 17:31249015-31249015 16
34 COSM6987300 NCOR1 soft tissue,fat,liposarcoma,myxoid-round cell c.4256C>T p.P1419L 17:16070422-16070422 16
35 COSM175679 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.536G>A p.R179H 1:45332794-45332794 16
36 COSM6978412 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.1022C>T p.P341L 1:45331816-45331816 16
37 COSM6987286 MLH1 soft tissue,fat,liposarcoma,myxoid-round cell c.2146G>A p.V716M 3:37050528-37050528 16
38 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 12:25245351-25245351 16
39 COSM6906365 KMT2C soft tissue,fat,liposarcoma,pleomorphic c.12200C>A p.P4067H 7:152154086-152154086 16
40 COSM6906367 KMT2A soft tissue,fat,liposarcoma,pleomorphic c.8086C>T p.R2696* 11:118503987-118503987 16
41 COSM6924116 KMT2A soft tissue,fat,liposarcoma,myxoid-round cell c.5783G>T p.G1928V 11:118498063-118498063 16
42 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 4:54731971-54731971 16
43 COSM216207 KDM6A soft tissue,fat,liposarcoma,pleomorphic c.3768C>G p.Y1256* 23:45090754-45090754 16
44 COSM1645298 JAK1 soft tissue,fat,liposarcoma,pleomorphic c.1595G>A p.R532H 1:64855562-64855562 16
45 COSM6987289 GATA2 soft tissue,fat,liposarcoma,myxoid-round cell c.436G>A p.G146S 3:128486162-128486162 16
46 COSM6664414 FLCN soft tissue,fat,liposarcoma,pleomorphic c.247G>A p.E83K 17:17227891-17227891 16
47 COSM6934579 FAT1 soft tissue,fat,liposarcoma,pleomorphic c.2806G>A p.V936I 4:186707022-186707022 16
48 COSM6934578 FAT1 soft tissue,fat,liposarcoma,pleomorphic c.2806G>A p.V936I 4:186707022-186707022 16
49 COSM6906369 ERBB2 soft tissue,fat,liposarcoma,pleomorphic c.2441G>A p.R814H 17:39724859-39724859 16
50 COSM1056635 EPHA5 soft tissue,fat,liposarcoma,pleomorphic c.1702G>A p.D568N 4:65404462-65404462 16

Expression for Myxoid Liposarcoma

Search GEO for disease gene expression data for Myxoid Liposarcoma.

Pathways for Myxoid Liposarcoma

Pathways related to Myxoid Liposarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 TP53 MDM2 IGF1R ERG CDK4
2 12.35 TP53 MIR135B MDM2 HMGA2
3 12.22 HMGA2 FUS EWSR1 ERG
4
Show member pathways
12.18 TP53 MDM2 IGF1R CEBPB
5
Show member pathways
12.02 TP53 MDM2 IGF1R CDK4
6 11.92 TP53 MDM2 CDK4 ATF1
7 11.91 TP53 MDM2 IGF1R CDK4
8 11.67 TP53 MDM2 IGF1R CDK4
9 11.64 TP53 MDM2 CDK4
10 11.63 TP53 NFKBIZ MDM2 IGF1R HMGA2 FUS
11 11.58 TP53 MDM2 IGF1R CEBPB
12 11.52 TP53 MDM2 CDK4
13 11.22 TP53 MDM2 CDK4
14 11.12 TP53 MDM2 CDK4 ATF1
15 11.05 TP53 MDM2 CDK4
16 10.8 TP53 DDIT3 CEBPB ATF1

GO Terms for Myxoid Liposarcoma

Cellular components related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CHOP-C/EBP complex GO:0036488 8.62 DDIT3 CEBPB

Biological processes related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.77 TP53 MDM2 HMGA2 DDIT3 CEBPB
2 regulation of transcription, DNA-templated GO:0006355 9.76 TP53 HMGA2 FUS EWSR1 ERG DDIT3
3 amyloid-beta clearance GO:0097242 9.32 LRP1 IGF1R
4 ER overload response GO:0006983 9.26 TP53 DDIT3
5 transcription by RNA polymerase II GO:0006366 9.1 CEBPB
6 cellular response to actinomycin D GO:0072717 8.96 TP53 MDM2
7 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 8.8 TP53 DDIT3 CEBPB

Molecular functions related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.46 TP53 HMGA2 DDIT3 CEBPB
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.35 TP53 HMGA2 ERG DDIT3 CEBPB
3 identical protein binding GO:0042802 9.17 TSN TP53 MDM2 IGF1R FUS EWSR1

Sources for Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....